Literature DB >> 2573712

Bromocriptine-induced decrease in blood pressure in conscious spontaneously hypertensive rats: evidence for a peripheral site of action.

M van den Buuse1, A C Lambrechts.   

Abstract

The aim of the study was to discover whether the dopamine agonist bromocriptine has a central or peripheral site of action on blood pressure. An intraperitoneal injection of bromocriptine (0.5 mg kg-1) induced a long-lasting decrease in blood pressure in conscious spontaneously hypertensive rats (SHR). This effect was blocked by peripheral pretreatment with haloperidol or domperidone, but not by central treatment with haloperidol. A central injection of bromocriptine had only minor effects on blood pressure. These results suggest that primarily peripheral, rather than central, mechanisms are involved in the hypotensive effects of bromocriptine.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2573712     DOI: 10.1111/j.2042-7158.1989.tb06549.x

Source DB:  PubMed          Journal:  J Pharm Pharmacol        ISSN: 0022-3573            Impact factor:   3.765


  6 in total

1.  Neurochemical profile of EMD 45609 (carmoxirole), a dopamine DA2-receptor agonist.

Authors:  A F Haase; H E Greiner; C A Seyfried
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1991-06       Impact factor: 3.000

Review 2.  Cardiovascular effects of melanocortins.

Authors:  Michael H Humphreys; Xi-Ping Ni; David Pearce
Journal:  Eur J Pharmacol       Date:  2011-01-01       Impact factor: 4.432

3.  Effects of the novel dopamine DA2-receptor agonist carmoxirole (EMD 45609) on noradrenergic and purinergic neurotransmission in rat isolated kidney.

Authors:  L C Rump; K Wilde; C Bohmann; P Schollmeyer
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1992-03       Impact factor: 3.000

4.  Dopamine receptor modulation of noradrenaline release by carmoxirole in human cortical kidney slices.

Authors:  L C Rump; E Schwertfeger; U Schaible; M J Schuster; A Frankenschmidt; P Schollmeyer
Journal:  Eur J Clin Pharmacol       Date:  1993       Impact factor: 2.953

5.  Evidence for a noradrenergic mechanism causing hypertension and abnormal glucose metabolism in rats with relative deficiency of gamma-melanocyte-stimulating hormone.

Authors:  Xi-Ping Ni; Claudia van Dijk; David Pearce; Michael H Humphreys
Journal:  Exp Physiol       Date:  2009-05-08       Impact factor: 2.969

6.  Neuroendocrine and metabolic components of dopamine agonist amelioration of metabolic syndrome in SHR rats.

Authors:  Michael Ezrokhi; Shuqin Luo; Yelena Trubitsyna; Anthony H Cincotta
Journal:  Diabetol Metab Syndr       Date:  2014-09-25       Impact factor: 3.320

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.